ArticleNPJ breast cancer2026
Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype with no effective targeted therapies. To identify novel therapeutic targets, we conducted transcriptome-wide association studies (TWAS) integrating genome-wide association studies (GWAS) summary statistics from the Breast Cancer Association Consortium (BCAC) and UK Biobank with expression quantitative trait loci (eQTL) summary statistics from breast mammary tissues via the Genotype-Tissue Expression (GTEx) study. Our approach identified novel candidate genes positively or negatively associated with TNBC based on their TWAS effect size. We validated these candidates by confirming their differential expression between TNBC and normal tissues using The Cancer Genome Atlas (TCGA) breast cancer cohort. Among these, Epidermal Growth Factor Receptor Pathway Substrate 15 Like 1 (EPS15L1) emerged as a top candidate significantly associated with TNBC. EPS15L1 was found to be overexpressed in basal-like and claudin-low TNBC tumors and cell lines, with its high expression correlating with poor prognosis. Functional studies demonstrated that EPS15L1 enhances TNBC cell growth, as evidenced by increased metabolic activity in high-density conditions, enhanced clonogenic ability in low-density settings, and improved 3D spheroid formation. Additionally, knockdown of EPS15L1 suppressed the formation and stellate morphology of single-cell-initiated spheroids within the 3D microenvironment. Collectively, these findings establish EPS15L1 as a driver of TNBC initiation, implying its potential as a biomarker for early detection and a target for prevention.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.